characteristic | training cohort | Validation cohort | ||||
---|---|---|---|---|---|---|
Positive for ALN metastasis(n = 106) | Negative for ALN metastasis (n = 190) | P value | Positive for ALN metastasis(n = 54) | Negative for ALN metastasis(n = 82) | P value | |
Age (mean ± SD) | 53.94 ± 9.66 | 53.84 ± 10.07 | 0.727 | 52.35 ± 11.14 | 53.20 ± 9.17 | 0.373 |
Tumor size (mm) | 20.37 ± 4.87 | 19.95 ± 4.67 | 0.723 | 20.44 ± 5.88 | 19.14 ± 4.72 | 0.500 |
Histological grade | Â | Â | <0.001* | Â | Â | <0.001* |
 I | 13 | 56 |  | 3 | 20 |  |
 II | 64 | 108 |  | 32 | 53 |  |
 III | 29 | 26 |  | 19 | 9 |  |
Multifocality | Â | Â | <0.001* | Â | Â | 0.001* |
 Yes | 53 | 54 |  | 29 | 19 |  |
 No | 53 | 136 |  | 25 | 63 |  |
MRI report LN status | Â | Â | <0.001* | Â | Â | 0.006* |
 Yes | 74 | 81 |  | 34 | 32 |  |
 No | 32 | 109 |  | 20 | 50 |  |
Estrogen receptor | Â | Â | 0.030* | Â | Â | 0.734 |
 Positive | 84 | 128 |  | 39 | 57 |  |
 Negative | 22 | 62 |  | 15 | 25 |  |
Progesterone receptor | Â | Â | 0.930 | Â | Â | 0.928 |
 Positive | 72 | 130 |  | 34 | 51 |  |
 Negative | 34 | 60 |  | 20 | 31 |  |
HER2 status | Â | Â | 0.340 | Â | Â | 0.897 |
 Positive | 30 | 64 |  | 12 | 19 |  |
 Negative | 76 | 126 |  | 42 | 63 |  |
Ki-67 status | Â | Â | 0.881 | Â | Â | 0.210 |
 Positive | 75 | 136 |  | 41 | 54 |  |
 Negative | 31 | 54 |  | 13 | 28 |  |
Radiomics score | −0.008(−0.55 to 0.36) | −1.642(−2.40 to −0.72) | <0.001* | 0.064(−0.47 to 0.52) | −1.613(−2.67 to −0.63) | <0.001* |